

Date: 13th August, 2026

To,
BSE Limited
Department of Corporate Services
P. J. Towers, Dalal Street,
Fort, Mumbai – 400001.
Scrip Code: 511523

Sub: Outcome of Board Meeting

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) (read with Schedule III) including circulars issued thereunder and other applicable provisions, if any, as amended from time to time, and in continuation to our intimation dated August 5, 2026 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. August 13, 2026 [commenced at 16:00 Hrs (IST) and concluded at 17:00 Hrs (IST)] has, inter-alia, considered and approved the following matters:

1. Approved Unaudited Financial Results for June 30, 2026 along with the Limited Review Report. Statement showing Unaudited Financial Results and Limited Review Report for the Quarter ended June 30, 2026 is enclosed as **Annexure-A**
2. Approved Director’s Report for the financial year ending 31st March, 2026.
3. The Board has decided to convene the 34th Annual General Meeting of the Company on Wednesday, 23rd September, 2026 at 04.00 P.M. through video conferencing.
4. **Resignation of Ms. Ashita Chittora (A50327), as Company Secretary and Compliance Officer of the Company w.e.f 13th August, 2026.**
The Board of Directors of the Company at its meeting held today i.e. on August 13, 2026, took note of the resignation tendered by Ms. Ashita Chittora as Company Secretary and Compliance Officer of Veerhealth Care Ltd with effect from the closure of the business hours of August 13, 2026, due to pursuance of better opportunity.

Further, detailed information as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, in respect of aforesaid resignation and the resignation letter is enclosed as **Annexure B**.

5. **Appointment of Ms. Ruchi Shah (Membership Number: A80942) as the Company Secretary & Compliance Officer of the Company.**
Pursuant to Regulation 30 and other applicable provisions, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors in its meeting held on August 13, 2026 has considered and approved the appointment of Ms. Ruchi Shah as the Company Secretary & Compliance Officer of the company in pursuance to the provisions of Section 203 of the Companies Act, 2013, read with

Rule 8 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and other applicable provisions, if any with effect from August 13, 2026.

Disclosure required pursuant to Regulation 30 of SEBI LODR read with Clause 7, Para A of Part A of Schedule III to the said Regulation read with the SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with regards to change in Directors and Key Managerial Personnel is enclosed as **Annexure - C**.

Ms. Ruchi Shah is related to the Directors or Key Managerial Personnel or Promoters of the Company. Her brief profile is annexed with this communication as **Annexure - C**.

Kindly take the above information on record and oblige.

Thanking You.

Yours faithfully,
For **Veerhealth Care Limited**

Bhavin S. Shah
Managing Director
DIN: 03129574



VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

Statement of Unaudited Financial Results for the Quarter ended June 30, 2026

(Amount in lakhs)

Sr. No.	Particulars	Standalone			
		Quarter ended 30-06-2026	Quarter ended 31-03-2026	Quarter ended 30-06-2025	Year ended 31-03-2026
		Unaudited	Audited	Unaudited	Audited
I	Revenue from operations	2492.56	1676.14	448.52	3248.45
II	Other Income	16.09	21.52	65.04	80.16
III	Total Revenue (I + II)	2508.65	1697.66	513.56	3328.61
IV	Expenses:				
	(a) Cost of materials consumed		0.00	0.00	0.00
	(b) Purchase of stock-in-trade	2551.38	1395.95	304.63	2615.44
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-516.29	16.35	47.96	-200.38
	(d) Employee benefits expense	66.27	44.34	44.07	171.40
	(e) Finance Costs	23.28	10.79	9.51	40.22
	(f) Depreciation and amortisation expense	35.93	34.79	27.85	129.13
	(g) Other expenses	200.42	146.42	55.48	416.01
	Total Expenses	2360.99	1648.64	489.50	3171.82
V	Profit/(Loss) before exceptional items (III - IV)	147.66	49.02	24.06	156.79
VI	Exceptional items	0.00	31.00	0.00	31.00
VII	Profit before tax (V - VI)	147.66	18.02	24.06	125.79
VIII	Tax expense:				
	1) Current Tax	25.00	4.00	0.00	22.00
	2) Prior Year Tax	0.00	0.00	0.00	0.00
	2) Deferred Tax	0.00	49.39	0.00	49.39
IX	Profit/(Loss) for the period (VII - VIII)	122.66	-35.37	24.06	54.40
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00
	(b) Income Tax effect on above	0.00	0.00	0.00	0.00
	Other Comprehensive Income	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX + X)	122.66	-35.37	24.06	54.40
XII	Paid-up equity share capital of Rs. 10 each	1999.85	1999.85	1999.85	1999.85
XIII	Other Equity	902.38	292.47	222.03	292.47
XIV	Net Worth	2902.23	2292.32	2221.88	2292.32
XV	Earnings Per Share (of Rs. 10 each):				
	(a) Basic (in Rs.)	0.61	-0.18	0.12	0.27
	(b) Diluted (in Rs.)	0.57	-0.18	0.12	0.27

VEERHEALTH CARE LIMITED

Regd Office: 629-A, Gazdar House, 1st Floor, J.S.S. Marg, Near Kalbadevi Post Office, Mumbai - 400002.

Tel. No. 022-22018582 CIN: L65910MH1992PLC067632

Email: info@veerhealthcare.net Website: www.veerhealthcare.net

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th August, 2026.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 During the quarter ended June 30, 2026 the Company is operating in a single segment i.e. 'Healthcare Pharma Products'. Accordingly, segment wise reporting is not applicable.
- 4 During the quarter, the Company received approval for the issue of 1,00,00,000 warrants, convertible into an equivalent number of equity shares of ₹10 each, on a preferential basis at an issue price of ₹20.25 per warrant, aggregating to ₹2,025 lakh, pursuant to the approval of the shareholders and in accordance with the applicable provisions of the SEBI ICDR Regulations. Consequent to the issue of the aforesaid warrants, an amount of ₹487.25 lakh has been received from the proposed allottees up to June 30, 2026, being part consideration towards the said warrants.
- 5 / regrouped wherever necessary.
- 6 The financial results of the Company are available at www.bseindia.com and at www.veerhealthcare.net.

By order of the Board
For Veerhealth Care Limited



Bhavin S. Shah
Managing Director
DIN: 03129574

Place: Mumbai
Date: 13th August, 2026





Independent Auditor's Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Veerhealth Care Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Ind-AS Financial Results of M/s. Veerhealth Care Limited ("the Company") for the quarter ended 30th June, 2026, together with the notes thereon attached herewith ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulation")
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We have conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
5. We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
6. Based our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Jayesh R Shah & Co.
Chartered Accountants
Firm Regn. No.104182W


Kruti Doshi

Partner

Membership No.605915

Place: Mumbai

Date: 13th August 2026

UDIN: 26605915KWZVNH8337



Annexure B

Details pursuant to Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No	Particulars	Details
1.	Reason for change viz. resignation	Ms. Ashita Chittora (A50327) has resigned from the Position of Company Secretary & Compliance Officer of the Company with effect from Thursday, August 13, 2026 to pursue better career opportunities. Ms. Ashita Chittora had confirmed that there are no other material reasons for his resignation other than one specified above.
2.	Date of cessation	13-08-2026
3.	Brief Profile (in case of Not applicable appointment)	NA
4.	Disclosure of relationships between Not applicable directors (In case of appointment of Director)	NA

ASHITA CHITTORA
C-367, Mahaveer Tuscan, Basvana Nagar Main Road,
Hoodi, Bengaluru, Karnataka - 560048

RESIGNATION LETTER

Date:- 13/08/2026

To,

The Board of Directors,

Veerhealth Care Ltd,

629-A, GAZDAR HOUSE, 1ST FLOOR, NEAR KALBADEVI POST

OFFICE, J.S.S. MARG, MUMBAI – 400002

Subject: Resignation from the post of Company Secretary of the Company

Dear Sir(s),

This is to inform you that, I hereby tender my resignation from the post of Company Secretary of Veerhealth Care Ltd with effect from **13th**

August, 2026.

I would like to thank you for providing me the opportunity to work for the organization and supporting me during the tenure of my job.

Thanking You,

Yours Faithfully,



Ashita Chittora

Membership No.: ACS-50327

Annexure C

Details pursuant to Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No	Particulars	Details
1.	Name	Ms. Ruchi Shah
2.	Reason for change viz. appointment	Ms. Ruchi Shah is appointed as the Company Secretary & Compliance Officer of the Company in place of Ms. Ashita Chittora who resigned in order to pursue an external opportunity.
2.	Date of appointment	13-08-2026
3.	Brief Profile (in case of Not applicable appointment)	Qualifications & Certifications: Bachelors in Banking and Insurance Company Secretary, Institute of Company, Secretaries of India Overall Experience: Over 6 years of experience in Corporate Laws, Legal, Secretarial and other related matters. Holds a challenging position that encourages growth and opportunities of working on versatile projects and handling confidential information with utmost discretion.
4.	Disclosure of relationships between directors (in case of appointment).	Ms. Ruchi Shah is daughter of Mr. Yogesh Shah who is Non-Executive - Non Independent Director-Chairperson of the Company.